The early bactericidal activity of rifabutin measured by sputum viable counts in Hong Kong patients with pulmonary tuberculosis.
Previously untreated patients with smear-positive pulmonary tuberculosis were randomly allocated to treatment with 600, 300, 150 or 75 mg doses of rifabutin (LM427, ansamycin), 600, 300 or 150 mg of rifampicin, 300 mg isoniazid or to no drug daily for 2 days. The fall in viable counts of Mycobacterium tuberculosis in sputum collections during the 2 days, termed the early bactericidal activity (EBA), was estimated from counts of colony-forming units (cfu) on selective 7H-11 agar medium. The EBA for rifabutin ranged from -0.039 (an increase in counts) to 0.049 log10 cfu/ml/day whereas the EBA increased from 0.071 for 150 mg rifampicin to 0.293 log10 cfu/ml/day for 600 mg rifampicin and was 0.43 log10 cfu/ml/day for 300 mg isoniazid. The difference between the EBAs for rifabutin and rifampicin just attained significance (P = 0.05) suggesting that rifabutin was inactive or less active than rifampicin against the extracellular bacilli in pulmonary cavities. Peak plasma concentrations of rifabutin after the initial doses were found to be proportional to dose size and were approximately 7 times lower than those after the same dose size of rifampicin. The lower EBA of rifabutin as compared to rifampicin is probably due to the low plasma concentrations which are not fully compensated for by slightly greater antituberculosis activity of rifabutin in vitro.
Chan
S L
SL
Grantham Hospital, Aberdeen, Hong Kong.
Yew
W W
WW
Ma
W K
WK
Girling
D J
DJ
Aber
V R
VR
Felmingham
D
D
Allen
B W
BW
Mitchison
D A
DA
D000293:Adolescent; D000328:Adult; D000995:Antitubercular Agents / Q000097:blood / Q000494:pharmacology* / Q000627:therapeutic use; D015169:Colony Count, Microbial; D004305:Dose-Response Relationship, Drug; D006723:Hong Kong; D006801:Humans; D007538:Isoniazid / Q000494:pharmacology / Q000627:therapeutic use; D009169:Mycobacterium tuberculosis / Q000187:drug effects* / Q000254:growth & development / Q000302:isolation & purification; D017828:Rifabutin; D012293:Rifampin / Q000097:blood / Q000494:pharmacology* / Q000627:therapeutic use; D012294:Rifamycins / Q000097:blood / Q000494:pharmacology* / Q000627:therapeutic use; D013183:Sputum / Q000382:microbiology*; D014397:Tuberculosis, Pulmonary / Q000097:blood / Q000188:drug therapy* / Q000382:microbiology
D000995:Antitubercular Agents; D012294:Rifamycins; D017828:Rifabutin; D007538:Isoniazid; D012293:Rifampin